MLTX
MoonLake Immunotherapeutics
Overview
MoonLake Immunotherapeutics develops SLK, a novel Nanobody inhibitor of IL-17A and IL-17F, for inflammatory skin and joint diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis.
MoonLake Immunotherapeutics is a Healthcare company operating in Biotechnology with a $1.63B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $-0.93—Rev— vs ——EODHD
- Q1 FY20262026-05-10EPS$-0.98 vs $-0.92-6.4%Rev— vs ——EODHD
- Q4 FY20252026-02-25EPS$-0.92 vs $-0.98+6.0%Rev$0 vs ——EODHD
- Q3 FY20252025-11-04EPS$-1.10 vs $-0.88-25.2%Rev$0 vs ——EODHD
- Q2 FY20252025-08-04EPS$-0.87 vs $-0.72-20.8%Rev$0 vs ——EODHD
- Q1 FY20252025-05-04EPS$-0.63 vs $-0.74+14.3%Rev$0 vs ——EODHD
- Q4 FY20242025-02-25EPS$-0.72 vs $-0.59-21.5%Rev$101.8K vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.56 vs $-0.44-27.3%Rev$0 vs ——EODHD
- Q2 FY20242024-08-06EPS$-0.39 vs $-0.28-39.3%Rev$0 vs ——EODHD
- Q1 FY20242024-05-06EPS$-0.22 vs $-0.19-15.8%Rev$19.7K vs ——EODHD
- Q4 FY20232024-02-28EPS$-0.12 vs $-0.23+47.8%Rev$19.7K vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.18 vs $-0.23+21.7%Rev$0 vs ——EODHD
- Q2 FY20232023-08-09EPS$-0.23 vs $-0.27+14.8%Rev$0 vs ——EODHD
- Q1 FY20232023-05-11EPS$-0.23 vs $-0.31+25.8%Rev$0 vs ——EODHD
- Q4 FY20222023-03-19EPS$-0.31 vs $-0.33+6.1%Rev$0 vs ——EODHD
- Q3 FY20222022-11-13EPS$-0.27 vs $-0.32+15.6%Rev$0 vs ——EODHD
- Q2 FY20222022-08-11EPS$-0.34 vs $-0.54+37.0%Rev$0 vs ——EODHD
- Q1 FY20222022-05-15EPS$-0.35 vs $-0.350.0%Rev$0 vs ——EODHD
- Q4 FY20212022-02-16EPS$-0.15 vs ——Rev— vs ——EODHD
- Q3 FY20212021-11-11EPS$-0.14 vs ——Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $-0.93 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $-0.98 | $-0.92 | -6.4% | — | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $-0.92 | $-0.98 | +6.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-1.10 | $-0.88 | -25.2% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-04 | $-0.87 | $-0.72 | -20.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $-0.63 | $-0.74 | +14.3% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.72 | $-0.59 | -21.5% | $101.8K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.56 | $-0.44 | -27.3% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.39 | $-0.28 | -39.3% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.22 | $-0.19 | -15.8% | $19.7K | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $-0.12 | $-0.23 | +47.8% | $19.7K | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.18 | $-0.23 | +21.7% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.23 | $-0.27 | +14.8% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-0.23 | $-0.31 | +25.8% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-19 | $-0.31 | $-0.33 | +6.1% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.27 | $-0.32 | +15.6% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.34 | $-0.54 | +37.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.35 | $-0.35 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-16 | $-0.15 | — | — | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-0.14 | — | — | $0 | — | — | EODHD |
Source: EODHD. MLTX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks MLTX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 90% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2023 | $0.74 | $0.67 | +10.4% | +6.4% | +5.5% |
| Q4 FY2023 | $0.76 | $0.70 | +8.7% | +0.8% | +0.3% |
| Q3 FY2023 | $0.60 | $0.57 | +5.3% | -3.4% | -2.5% |
| Q2 FY2023 | $0.63 | $0.64 | -2.0% | +3.6% | +3.6% |
| Q1 FY2022 | $0.82 | $0.77 | +6.2% | +5.9% | +8.9% |
| Q4 FY2022 | $0.74 | $0.76 | -2.5% | +4.4% | +4.7% |
| Q3 FY2022 | $0.63 | $0.62 | +1.1% | +6.9% | +4.8% |
| Q2 FY2022 | $0.84 | $0.80 | +4.7% | +5.9% | +8.2% |
| Q1 FY2021 | $0.82 | $0.74 | +11.4% | +7.7% | +7.5% |
| Q4 FY2021 | $0.86 | $0.79 | +8.6% | +3.3% | +2.5% |
Guidance change history
Sample- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Raised2023-10-15
- Q2 FY2023Suspended2023-07-15
- Q1 FY2022Raised2022-04-15
- Q4 FY2022Maintained2022-13-15
- Q3 FY2022Maintained2022-10-15
- Q2 FY2022Raised2022-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Da Silva Jorge SantosCEO2 yr 4 mono recorded callsCurrentSample
CEO since 2024 • 1/2 beats (50%) • last guidance raise Q2 FY2023
- Matthias BodenstedtCFO1 yr 4 mo1 callCurrentSample
CFO since 2025 • 1/2 beats (50%) • last guidance raise Q3 FY2023
- Kristian ReichChief Scientific Officer2 yr 4 mo1 callCurrentSample
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • last guidance raise Q3 FY2023
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MLTX.
$ curl https://api.spokenalpha.com/v1/companies/MLTXFAQ
Frequently asked about MLTX
Where can I find MoonLake Immunotherapeutics's (MLTX) earnings call transcripts?
Spoken Alpha indexes MLTX's earnings call transcripts at https://spokenalpha.com/companies/MLTX. Each call links to attributed speakers and parsed analyst Q&A. MoonLake Immunotherapeutics's own investor relations page is at https://ir.moonlaketx.com/.
When was MoonLake Immunotherapeutics's most recent earnings call?
MoonLake Immunotherapeutics (MLTX) held its most recent earnings call on 2025-09-29, covering fiscal Q1 2023.
What sector is MLTX in?
MoonLake Immunotherapeutics (MLTX) operates in the Healthcare sector (Biotechnology industry).